JNK inhibition shows promise for SMA

Laxman Gangwani outlines the results of a preclinical study showing that JNK inhibition is a promising therapeutic strategy for spinal muscular atrophy, and discusses how this approach might impact the treatment landscape if shown to be beneficial in clinical trials (4:22).